Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIM-DJ2727 (FMT) in Active Ulcerative Colitis
NCT05786404Phase 1Recruiting
- Sponsor
- UTHealth Houston
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PRIM-DJ2727 in ulcerative colitis (UC) (2 arms), sponsored by UTHealth Houston. Primary endpoints: Disease severity as assessed by the Partial Mayo Score (PMS) at week 5, Change in fecal microbiota diversity and genera at week 4 and 2 more. Started Dec 2023; status: recruiting.
02
Drugs
PRIM-DJ2727
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05786404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786404.